Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
frameshift-derived neoantigen-loaded dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This is an autologous dendritic cell-based cancer vaccine developed by Radboud University Medical Center for the prevention and treatment of microsatellite instability (MSI)-positive colorectal cancer, particularly in patients with Lynch syndrome. The vaccine is a personalized immunotherapy that utilizes a patient's own dendritic cells loaded ex vivo with peptides derived from frameshift mutations (neoantigens) characteristic of mismatch repair-deficient tumors. These neoantigens arise from mutations in coding microsatellites of genes such as TGF-beta receptor II and caspase-5. Additionally, the vaccine targets the tumor-associated antigen carcinoembryonic antigen (CEA). By presenting these specific antigens, the vaccine aims to stimulate a robust T-cell mediated immune response to recognize and eliminate precancerous or cancerous cells expressing these markers.
- Other names
- DC vaccinationFSP-loaded DC vaccineframeshift peptide-loaded dendritic cell vaccineneoantigen-loaded dendritic cell vaccine
02
Targets
Caspase-5 frameshift-derived peptidePt-DNA adduct (DNA-oxaliplatin adduct)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on frameshift-derived neoantigen-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on frameshift-derived neoantigen-loaded dendritic cell vaccine.